Orphanet Journal of Rare Diseases, ISSN 1750-1172, 2011, Volume 6, Issue 1, pp. 60 - 60
Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia, thrombocytopenia and renal impairment. Atypical HUS (aHUS) defines non...
Plasma exchange | Factor H | Combined liver-kidney transplantation | Plasma infusion | Factor B | Atypical hemolytic uremic syndrome | Eculizumab | Membrane cofactor protein | Thrombomodulin | Factor I | Kidney transplantation | MEDICINE, RESEARCH & EXPERIMENTAL | factor I | CFHR1/CFHR3 DEFICIENCY | LIVER-KIDNEY TRANSPLANTATION | plasma infusion | kidney transplantation | eculizumab | factor B | THROMBOTIC THROMBOCYTOPENIC PURPURA | SUCCESSFUL RENAL-TRANSPLANTATION | factor H | combined liver-kidney transplantation | INHIBITOR ECULIZUMAB | ALTERNATIVE PATHWAY | membrane cofactor protein | thrombomodulin | GENETICS & HEREDITY | plasma exchange | SUCCESSFUL PLASMA THERAPY | FACTOR-I MUTATIONS | COMPLEMENT-FACTOR-H | Complement Activation | Humans | Middle Aged | Child, Preschool | Complement System Proteins - immunology | Infant | Male | Hemolytic-Uremic Syndrome - epidemiology | Young Adult | Hemolytic-Uremic Syndrome - genetics | Hemolytic-Uremic Syndrome - physiopathology | Aged, 80 and over | Adult | Complement System Proteins - genetics | Female | Hemolytic-Uremic Syndrome - therapy | Child | Infant, Newborn | Risk Factors | Kidney Transplantation | Animals | Adolescent | Aged | Mice | Mutation | Atypical Hemolytic Uremic Syndrome | Viral antibodies | Usage | Care and treatment | Antibodies | Genetic aspects | Research | Diagnosis | Health aspects | Genetic screening | Hemolytic-uremic syndrome | Risk factors | Lupus | Plasma | E coli | Disease | Vascular endothelial growth factor | Streptococcus infections
Plasma exchange | Factor H | Combined liver-kidney transplantation | Plasma infusion | Factor B | Atypical hemolytic uremic syndrome | Eculizumab | Membrane cofactor protein | Thrombomodulin | Factor I | Kidney transplantation | MEDICINE, RESEARCH & EXPERIMENTAL | factor I | CFHR1/CFHR3 DEFICIENCY | LIVER-KIDNEY TRANSPLANTATION | plasma infusion | kidney transplantation | eculizumab | factor B | THROMBOTIC THROMBOCYTOPENIC PURPURA | SUCCESSFUL RENAL-TRANSPLANTATION | factor H | combined liver-kidney transplantation | INHIBITOR ECULIZUMAB | ALTERNATIVE PATHWAY | membrane cofactor protein | thrombomodulin | GENETICS & HEREDITY | plasma exchange | SUCCESSFUL PLASMA THERAPY | FACTOR-I MUTATIONS | COMPLEMENT-FACTOR-H | Complement Activation | Humans | Middle Aged | Child, Preschool | Complement System Proteins - immunology | Infant | Male | Hemolytic-Uremic Syndrome - epidemiology | Young Adult | Hemolytic-Uremic Syndrome - genetics | Hemolytic-Uremic Syndrome - physiopathology | Aged, 80 and over | Adult | Complement System Proteins - genetics | Female | Hemolytic-Uremic Syndrome - therapy | Child | Infant, Newborn | Risk Factors | Kidney Transplantation | Animals | Adolescent | Aged | Mice | Mutation | Atypical Hemolytic Uremic Syndrome | Viral antibodies | Usage | Care and treatment | Antibodies | Genetic aspects | Research | Diagnosis | Health aspects | Genetic screening | Hemolytic-uremic syndrome | Risk factors | Lupus | Plasma | E coli | Disease | Vascular endothelial growth factor | Streptococcus infections
Journal Article
Seminars in Nephrology, ISSN 0270-9295, 2013, Volume 33, Issue 6, pp. 508 - 530
Summary Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The atypical form of HUS is...
Nephrology | factor I | membrane cofactor protein | thrombomodulin | transplantation | Complement | eculizumab | factor H | hemolytic uremic syndrome | Factor H | Hemolytic uremic syndrome | Eculizumab | Membrane cofactor protein | Transplantation | Thrombomodulin | Factor I | C-REACTIVE PROTEIN | LIVER-KIDNEY TRANSPLANTATION | BONE-MARROW-TRANSPLANTATION | CLINICAL CHARACTERISTICS | RENAL-TRANSPLANTATION | THROMBOTIC THROMBOCYTOPENIC PURPURA | FACTOR-I | ENDOTHELIAL-CELLS | UROLOGY & NEPHROLOGY | COMPLEMENT-FACTOR-H
Nephrology | factor I | membrane cofactor protein | thrombomodulin | transplantation | Complement | eculizumab | factor H | hemolytic uremic syndrome | Factor H | Hemolytic uremic syndrome | Eculizumab | Membrane cofactor protein | Transplantation | Thrombomodulin | Factor I | C-REACTIVE PROTEIN | LIVER-KIDNEY TRANSPLANTATION | BONE-MARROW-TRANSPLANTATION | CLINICAL CHARACTERISTICS | RENAL-TRANSPLANTATION | THROMBOTIC THROMBOCYTOPENIC PURPURA | FACTOR-I | ENDOTHELIAL-CELLS | UROLOGY & NEPHROLOGY | COMPLEMENT-FACTOR-H
Journal Article
Seminars in Immunopathology, ISSN 1863-2297, 7/2014, Volume 36, Issue 4, pp. 399 - 420
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy defined by thrombocytopenia, nonimmune microangiopathic hemolytic anemia, and acute renal...
Biomedicine | Immunology | Complement system activation | aHUS | Eculizumab | Internal Medicine | STEC-HUS | Pneumococcal-HUS | THOMSEN-FRIEDENREICH ANTIGEN | OF-FUNCTION MUTATION | LIVER-KIDNEY TRANSPLANTATION | ESCHERICHIA-COLI O157-H7 | THROMBOTIC THROMBOCYTOPENIC PURPURA | SHIGA-TOXIN | IMMUNOLOGY | PATHOLOGY | VON-WILLEBRAND-FACTOR | THERAPEUTIC PLASMA-EXCHANGE | MEMBRANE COFACTOR PROTEIN | COMPLEMENT-FACTOR-H | Hemolytic-Uremic Syndrome - pathology | Pneumococcal Infections - epidemiology | Pneumococcal Infections - immunology | Humans | Pneumococcal Infections - pathology | Complement System Proteins - immunology | Complement Activation - immunology | Hemolytic-Uremic Syndrome - immunology | Hemolytic-Uremic Syndrome - epidemiology | Streptococcus pneumoniae - immunology | Bacteria | Pneumonia | Anemia | Bacterial pneumonia
Biomedicine | Immunology | Complement system activation | aHUS | Eculizumab | Internal Medicine | STEC-HUS | Pneumococcal-HUS | THOMSEN-FRIEDENREICH ANTIGEN | OF-FUNCTION MUTATION | LIVER-KIDNEY TRANSPLANTATION | ESCHERICHIA-COLI O157-H7 | THROMBOTIC THROMBOCYTOPENIC PURPURA | SHIGA-TOXIN | IMMUNOLOGY | PATHOLOGY | VON-WILLEBRAND-FACTOR | THERAPEUTIC PLASMA-EXCHANGE | MEMBRANE COFACTOR PROTEIN | COMPLEMENT-FACTOR-H | Hemolytic-Uremic Syndrome - pathology | Pneumococcal Infections - epidemiology | Pneumococcal Infections - immunology | Humans | Pneumococcal Infections - pathology | Complement System Proteins - immunology | Complement Activation - immunology | Hemolytic-Uremic Syndrome - immunology | Hemolytic-Uremic Syndrome - epidemiology | Streptococcus pneumoniae - immunology | Bacteria | Pneumonia | Anemia | Bacterial pneumonia
Journal Article
Journal of the American Society of Nephrology, ISSN 1046-6673, 2005, Volume 16, Issue 4, pp. 1035 - 1050
THROMBOTIC-THROMBOCYTOPENIC PURPURA | COFACTOR PROTEIN CD46 | SHIGELLA-DYSENTERIAE SEROTYPE-1 | COMPLEMENT FACTOR-H | ESCHERICHIA-COLI O157-H7 | PROGNOSTIC-FACTORS | UROLOGY & NEPHROLOGY | MICROVASCULAR ENDOTHELIAL-CELLS | THERAPEUTIC PLASMA-EXCHANGE | SHIGA-LIKE TOXINS | RENAL-TRANSPLANTATION | Hemolytic-Uremic Syndrome - genetics | Hemolytic-Uremic Syndrome - etiology | Phenotype | Humans | Europe - epidemiology | Hemolytic-Uremic Syndrome - therapy | North America - epidemiology | Hemolytic-Uremic Syndrome - epidemiology | Shiga Toxins | Incidence
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2009, Volume 361, Issue 17, pp. 1676 - 1687
The hemolytic–uremic syndrome, which is characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal impairment, occurs most frequently in young...
Complement Factor H - immunology | Autoantibodies - metabolism | Prognosis | Humans | Penetrance | Kidney Transplantation | Kidney Glomerulus - pathology | Hemolytic-Uremic Syndrome - classification | Complement System Proteins - metabolism | Hemolytic-Uremic Syndrome - genetics | Point Mutation | Complement System Proteins - genetics | Hemolytic-Uremic Syndrome - therapy | Complement Pathway, Alternative - genetics | Mutation | Complement Factor H - genetics | Care and treatment | Hemolytic-uremic syndrome | Diagnosis
Complement Factor H - immunology | Autoantibodies - metabolism | Prognosis | Humans | Penetrance | Kidney Transplantation | Kidney Glomerulus - pathology | Hemolytic-Uremic Syndrome - classification | Complement System Proteins - metabolism | Hemolytic-Uremic Syndrome - genetics | Point Mutation | Complement System Proteins - genetics | Hemolytic-Uremic Syndrome - therapy | Complement Pathway, Alternative - genetics | Mutation | Complement Factor H - genetics | Care and treatment | Hemolytic-uremic syndrome | Diagnosis
Journal Article
Pediatric Clinics of North America, ISSN 0031-3955, 02/2019, Volume 66, Issue 1, pp. 235 - 246
Hemolytic uremic syndrome (HUS) is the clinical triad of thrombocytopenia, anemia, and acute kidney injury. Classically associated with enterocolitis from...
Pneumococcal HUS | Cobalamin C | Atypical HUS | Hemolytic uremic syndrome | Shiga toxin | Escherichia coli | ACTIVATION | DIARRHEA | FUNCTIONAL TESTS | COMPLEMENT INHIBITOR ECULIZUMAB | ESCHERICHIA-COLI | RISK | RELATIVE NEPHROPROTECTION | PEDIATRIC-PATIENTS | NEUROLOGICAL INVOLVEMENT | PEDIATRICS | ANTIBIOTIC-TREATMENT | Fluid Therapy | Diagnosis, Differential | Hemolytic-Uremic Syndrome - etiology | Antibodies, Monoclonal, Humanized - therapeutic use | Prognosis | Erythrocyte Transfusion | Humans | Risk Factors | Kidney Transplantation | Plasma Exchange | Hemolytic-Uremic Syndrome - therapy | Hemolytic-Uremic Syndrome - diagnosis | Streptococcal Infections - complications | Escherichia coli Infections - complications | Renal Dialysis
Pneumococcal HUS | Cobalamin C | Atypical HUS | Hemolytic uremic syndrome | Shiga toxin | Escherichia coli | ACTIVATION | DIARRHEA | FUNCTIONAL TESTS | COMPLEMENT INHIBITOR ECULIZUMAB | ESCHERICHIA-COLI | RISK | RELATIVE NEPHROPROTECTION | PEDIATRIC-PATIENTS | NEUROLOGICAL INVOLVEMENT | PEDIATRICS | ANTIBIOTIC-TREATMENT | Fluid Therapy | Diagnosis, Differential | Hemolytic-Uremic Syndrome - etiology | Antibodies, Monoclonal, Humanized - therapeutic use | Prognosis | Erythrocyte Transfusion | Humans | Risk Factors | Kidney Transplantation | Plasma Exchange | Hemolytic-Uremic Syndrome - therapy | Hemolytic-Uremic Syndrome - diagnosis | Streptococcal Infections - complications | Escherichia coli Infections - complications | Renal Dialysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 23, pp. 2169 - 2181
This article describes the use of eculizumab in patients with atypical hemolytic–uremic syndrome. This C5 inhibitor was associated with improvement in...
MEDICINE, GENERAL & INTERNAL | IMPACT | PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA | INSIGHTS | Humans | Middle Aged | Hemolytic-Uremic Syndrome - blood | Male | Plasma Exchange | Young Adult | Hemolytic-Uremic Syndrome - genetics | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - blood | Adult | Female | Hemolytic-Uremic Syndrome - therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Kidney Diseases - drug therapy | Combined Modality Therapy | Thrombotic Microangiopathies - prevention & control | Platelet Count | Adolescent | Quality of Life | Aged | Kidney Diseases - etiology | Mutation | Complement C5 - antagonists & inhibitors | Hemolytic-Uremic Syndrome - drug therapy | Plasma | Adolescence | Thrombotic microangiopathy | Renal function | Complement inhibitors | Toxicity | Mortality | Clinical trials | Complement | Glomerular filtration rate | Defects | Quality of life | Studies | Platelets | Index Medicus | Abridged Index Medicus | Clinical Medicine | Pediatrics | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Pediatrik
MEDICINE, GENERAL & INTERNAL | IMPACT | PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA | INSIGHTS | Humans | Middle Aged | Hemolytic-Uremic Syndrome - blood | Male | Plasma Exchange | Young Adult | Hemolytic-Uremic Syndrome - genetics | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - blood | Adult | Female | Hemolytic-Uremic Syndrome - therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Kidney Diseases - drug therapy | Combined Modality Therapy | Thrombotic Microangiopathies - prevention & control | Platelet Count | Adolescent | Quality of Life | Aged | Kidney Diseases - etiology | Mutation | Complement C5 - antagonists & inhibitors | Hemolytic-Uremic Syndrome - drug therapy | Plasma | Adolescence | Thrombotic microangiopathy | Renal function | Complement inhibitors | Toxicity | Mortality | Clinical trials | Complement | Glomerular filtration rate | Defects | Quality of life | Studies | Platelets | Index Medicus | Abridged Index Medicus | Clinical Medicine | Pediatrics | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Pediatrik
Journal Article
Nature Genetics, ISSN 1061-4036, 05/2013, Volume 45, Issue 5, pp. 531 - 536
Pathologic thrombosis is a major cause of mortality. Hemolytic-uremic syndrome (HUS) features episodes of small-vessel thrombosis resulting in microangiopathic...
PROTEIN-KINASE-C | ACTIVATION | HUMAN-PLATELETS | GENETICS & HEREDITY | MICROANGIOPATHY | VASCULAR ENDOTHELIAL-CELLS | DIACYLGLYCEROL KINASES | INHIBITOR | ASSOCIATION | EXPRESSION | EPSILON | Hemolytic-Uremic Syndrome - etiology | Renal Insufficiency, Chronic | Genes, Recessive - genetics | Humans | Child, Preschool | Molecular Sequence Data | Infant | Male | Acute Kidney Injury - genetics | Mutation - genetics | Diacylglycerol Kinase - genetics | Immunoenzyme Techniques | Thrombotic Microangiopathies - genetics | Hemolytic-Uremic Syndrome - pathology | Thrombocytopenia - genetics | Exome - genetics | Female | Atypical Hemolytic Uremic Syndrome | Child | Care and treatment | Gene mutations | Von Willebrand factor | Genetic aspects | Research | Health aspects | Hemolytic-uremic syndrome | Risk factors | Proteins | Studies | Confidence intervals | Pediatrics | Genealogy | Genetics | Amino acids | Genomes | Mutation | Age | Data bases | Siblings | Life Sciences
PROTEIN-KINASE-C | ACTIVATION | HUMAN-PLATELETS | GENETICS & HEREDITY | MICROANGIOPATHY | VASCULAR ENDOTHELIAL-CELLS | DIACYLGLYCEROL KINASES | INHIBITOR | ASSOCIATION | EXPRESSION | EPSILON | Hemolytic-Uremic Syndrome - etiology | Renal Insufficiency, Chronic | Genes, Recessive - genetics | Humans | Child, Preschool | Molecular Sequence Data | Infant | Male | Acute Kidney Injury - genetics | Mutation - genetics | Diacylglycerol Kinase - genetics | Immunoenzyme Techniques | Thrombotic Microangiopathies - genetics | Hemolytic-Uremic Syndrome - pathology | Thrombocytopenia - genetics | Exome - genetics | Female | Atypical Hemolytic Uremic Syndrome | Child | Care and treatment | Gene mutations | Von Willebrand factor | Genetic aspects | Research | Health aspects | Hemolytic-uremic syndrome | Risk factors | Proteins | Studies | Confidence intervals | Pediatrics | Genealogy | Genetics | Amino acids | Genomes | Mutation | Age | Data bases | Siblings | Life Sciences
Journal Article